Literature DB >> 26360054

A comparison between genetically humanized and chimeric liver humanized mouse models for studies in drug metabolism and toxicity.

Nico Scheer1, Ian D Wilson2.   

Abstract

Mice that have been genetically humanized for proteins involved in drug metabolism and toxicity and mice engrafted with human hepatocytes are emerging and promising in vivo models for an improved prediction of the pharmacokinetic, drug-drug interaction and safety characteristics of compounds in humans. The specific advantages and disadvantages of these models should be carefully considered when using them for studies in drug discovery and development. Here, an overview on the corresponding genetically humanized and chimeric liver humanized mouse models described to date is provided and illustrated with examples of their utility in drug metabolism and toxicity studies. We compare the strength and weaknesses of the two different approaches, give guidance for the selection of the appropriate model for various applications and discuss future trends and perspectives.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26360054     DOI: 10.1016/j.drudis.2015.09.002

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  19 in total

1.  Observation of Clinically Relevant Drug Interaction in Chimeric Mice with Humanized Livers: The Case of Valproic Acid and Carbapenem Antibiotics.

Authors:  Eiko Suzuki; Kumiko Koyama; Daisuke Nakai; Ryoya Goda; Hiroshi Kuga; Kan Chiba
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-12       Impact factor: 2.441

Review 2.  Case examples of an evaluation of the human relevance of the pyrethroids/pyrethrins-induced liver tumours in rodents based on the mode of action.

Authors:  Tomoya Yamada
Journal:  Toxicol Res (Camb)       Date:  2018-01-16       Impact factor: 3.524

Review 3.  P450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity.

Authors:  Karl-Dimiter Bissig; Weiguo Han; Mercedes Barzi; Nataliia Kovalchuk; Liang Ding; Xiaoyu Fan; Francis P Pankowicz; Qing-Yu Zhang; Xinxin Ding
Journal:  Drug Metab Dispos       Date:  2018-08-09       Impact factor: 3.922

Review 4.  Human relevance of rodent liver tumour formation by constitutive androstane receptor (CAR) activators.

Authors:  Brian G Lake
Journal:  Toxicol Res (Camb)       Date:  2018-03-12       Impact factor: 3.524

5.  Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice.

Authors:  Kelly R Long; Elena Lomonosova; Qilan Li; Nathan L Ponzar; Juan A Villa; Erin Touchette; Stephen Rapp; R Matt Liley; Ryan P Murelli; Alexandre Grigoryan; R Mark Buller; Lisa Wilson; John Bial; John E Sagartz; John E Tavis
Journal:  Antiviral Res       Date:  2017-11-10       Impact factor: 5.970

Review 6.  Mouse Systems Genetics as a Prelude to Precision Medicine.

Authors:  Hao Li; Johan Auwerx
Journal:  Trends Genet       Date:  2020-02-06       Impact factor: 11.639

Review 7.  Animal models to study bile acid metabolism.

Authors:  Jianing Li; Paul A Dawson
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-05-18       Impact factor: 5.187

Review 8.  Aryl hydrocarbon receptor (AHR): "pioneer member" of the basic-helix/loop/helix per-Arnt-sim (bHLH/PAS) family of "sensors" of foreign and endogenous signals.

Authors:  Daniel W Nebert
Journal:  Prog Lipid Res       Date:  2017-06-09       Impact factor: 16.195

9.  Species differences in the pharmacokinetics of cefadroxil as determined in wildtype and humanized PepT1 mice.

Authors:  Yongjun Hu; David E Smith
Journal:  Biochem Pharmacol       Date:  2016-03-12       Impact factor: 5.858

10.  New technologies in drug metabolism and toxicity screening: organ-to-organ interaction.

Authors:  Abhinav Bhushan; Nicole J Martucci; O Berk Usta; Martin L Yarmush
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-03-21       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.